Mobile
  • Search
  • Advanced search
  • Multi-criteria search
  • Who are we ?
  • Log in
  • Sign up
  • Français
  • English

Kusajili – Clinical trials directory

Your research

Clear all filters

Filtres
organs
  • Côlon ou Rectum (colorectal) (1)
  • Estomac (1)
  • Oesophage (1)
  • Prostate (1)
  • Sein (1)
Specialty
  • Immunothérapie - Vaccinothérapie (1)
Type
  • Cancer colorectal métastatique (1)
  • Cancer de l'estomac (1)
  • Cancer de l'œsophage (1)
  • Cancer de la prostate (1)
  • Cancer du sein triple négatif (1)
Promoter
  • Gustave Roussy (IGR) Centre de Lutte Contre le Cancer (CLCC) de Villejuif (1)
Country
  • France (1)
Source
  • e-cancer.fr (1)
Phase

organs: Estomac
Gustave Roussy (IGR) Centre de Lutte Contre le Cancer (CLCC) de Villejuif Update Il y a 4 ans

Étude MATILDA : étude de phase 2 évaluant un traitement associant le durvalumab (anti-PDL1) et le tremelimumab (anti-CTLA4), chez des patients ayant une tumeur solide présentant une charge mutationnelle élevée. [essai clos aux inclusions] Essai de phase 2 de combinaison du Durvalumab (anti-PDL1) au Tremelimumab (anti-CTLA4) chez les patients atteints de tumeur solide présentant une charge mutationnelle élevée.

  • Country France,
  • organs Côlon ou Rectum (colorectal), Sein, Prostate, Oesophage, Estomac,
  • Specialty Immunothérapie - Vaccinothérapie,
Essai clos aux inclusions
More information

  • 1

Who are we ?

Kusajili was created to respond to a request from physicians to simplify access to patient registries and inclusion. Kusajili is regularly updated according to new French and international trials. [email protected]

Kusajili and MyHomeDoctor

MyHomeDoctor software unique to the world, created with surgeons, for follow-up and analysis of patient follow-up. Kusajili and MyHomeDoctor partners, help clinical research through improved patient follow-up and automatic inclusion.

Sign up

Sign up
Français - English - CGU - Cookies

©2023 Kusajili France - Kusajili International - MedSynApps - MyHomeDoctor.